Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H43N13O10 |
Molecular Weight | 685.69 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CCNC(=N)N1)[C@]2([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC2=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O
InChI
InChIKey=HPWIIERXAFODPP-GHBBWTPBSA-N
InChI=1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4308717Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4308717
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483
Enviomycin, antimicrobial drug, was isolated in Japan from fermentation broth of Syteptomyces griseoverticillatus var tuberacticus. This drug, a water-soluble, basic peptide, is effective against tubercle bacilli as well as some gram-positive and gram-negative bacteria. It is related to viomycin and cepreomycin in some of its physicochemical properties. It is used for the treatment of Mycobacterium avium caused lung diseases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0000372 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7509881 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[A case of pulmonary Mycobacterium fortuitum infection successfully treated with Kampo treatments]. | 2006 Aug |
|
[Case of pulmonary multi-drug resistant tuberculosis with left destroyed lung, treated with pneumonectomy]. | 2007 Jul |
|
[Case of multi-drug resistant pulmonary tuberculosis with bilateral cavitary lesions successfully treated by surgical treatment]. | 2007 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2539957
1 g/day three times weekly
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1406364
Enviomycin is bactericidal against Mycobacterium avium strain 13887 with MIC=1.6 ug/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3180
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
100000080241
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL2146142
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
m4924
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
XU299C23A2
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
33103-22-9
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
SUB06554MIG
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
Enviomycin
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
DTXSID901027569
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
DB08993
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
3577
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
C169954
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
20055267
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
D004776
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | |||
|
m11253
Created by
admin on Fri Dec 15 16:19:48 GMT 2023 , Edited by admin on Fri Dec 15 16:19:48 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)